Ekdv-691 Portable Jun 2026

| Attribute | Details | |-----------|---------| | | EKDV‑691 (development code) | | Chemical class | Ortho‑aryl‑pyrimidine small‑molecule kinase inhibitor | | Primary target | Dual inhibition of TGF‑β‑type I receptor (ALK5) and DDR1 (Discoidin Domain‑Receptor‑1) | | Therapeutic focus | Fibrotic diseases (idiopathic pulmonary fibrosis, systemic sclerosis) and oncology (desmoplastic tumours) | | Developer | Evoke Therapeutics, Inc. (formerly EK‑Discovery) | | Current status (April 2026) | IND filed (US, EU); Phase I dose‑escalation completed; Phase Ib/IIa trial launched in idiopathic pulmonary fibrosis (IPF) (NCT05891234) | | Formulation | Oral tablets (10 mg, 30 mg, 60 mg) | | Key differentiators | Simultaneous blockade of fibrogenic TGF‑β signaling and collagen‑receptor mediated matrix remodeling; favourable PK/PD profile with once‑daily dosing; low off‑target activity on the cardiac hERG channel. |

If you are looking to deploy or resolve this specific identifier in your local system, please let me know: EKDV-691

Inspect the casing of the component for secondary markings. Look for: | Attribute | Details | |-----------|---------| | |

Sometimes, late at night, Mira would sit in her kitchen and listen for the cylinder’s hum in the deep of the city—the sound of a memory refusing extinction by choosing to be remembered, not stored. Look for: Sometimes, late at night, Mira would

The three-digit suffix typically indicates the specific model iteration, performance rating (such as 690V power compatibility), physical dimensions, or chronological release sequence within that specific product line. Primary Industry Categories for the EKDV Series

Maria had been part of the team that discovered EKDV-691 deep within an Egyptian tomb, buried alongside pharaohs of old. Initial scans suggested it was not of this Earth, a relic from a civilization far more advanced than any humanity had ever known.

Rafiq, now a member of the , wrote the final report: